Daven Smith
Payments from drug & device makers
Across 418 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$858
- Johnson & Johnson$699
- Aimmune Therapeutics, Inc.$434
- Madrigal Pharmaceuticals$370
- Phathom Pharmaceuticals, Inc.$355
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,630100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $1,468 |
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $858 |
| Johnson & Johnson | 39 | $699 |
| Aimmune Therapeutics, Inc. | 29 | $434 |
| Madrigal Pharmaceuticals | 15 | $370 |
| Phathom Pharmaceuticals, Inc. | 26 | $355 |
| Pfizer | 34 | $346 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $295 |
| Sanofi | 12 | $241 |
| Gilead | 9 | $228 |
| Ardelyx, Inc. | 12 | $226 |
| Celltrion USA Inc. | 9 | $191 |
| Regeneron Healthcare Solutions, Inc. | 10 | $175 |
| Organon | 11 | $125 |
| Merck | 4 | $85 |
| Lilly USA, LLC | 4 | $73 |
| Boehringer Ingelheim | 3 | $72 |
| Intercept Pharmaceuticals, Inc. | 4 | $70 |
| Sandoz | 4 | $64 |
| Enterra Medical, Inc. | 1 | $60 |
| Fresenius Kabi USA, LLC | 3 | $53 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| Boston Scientific | 1 | $41 |
| QOL Medical, LLC | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Orphalan Inc | 1 | $15 |
How this compares
$6,660 in reported general payments places this provider in the 95th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lubiprostone | 16 | $2,229 |
| Colestipol Hcl | 35 | $2,092 |
| Sucralfate | 13 | $960 |
| Pantoprazole Sodium | 33 | $635 |
| Omeprazole | 33 | $440 |
Paid to pharmacies, not to this prescriber.
Other family in Provo
- Kindra HuntProvo$118K
- Judd HunterProvo$32K
- Katelyn SianoProvo$29K
- Michael RobinsonProvo$16K
- Darin UsherProvo$15K
- Ashley RadmallProvo$8K
- Kylee MaliwaukiProvo$8K
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.